BMP7: A new bone metastases prevention?

American Journal of Pathology

Volumn 171, Issue 3, 2007, Pages 739-743

  Fournier, Pierrick G J ^a   Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

BONE DESTRUCTION; BONE METASTASIS; CANCER CELL; CELL DIFFERENTIATION; CELL MIGRATION; CORRELATION ANALYSIS; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICRODISSECTION; NONHUMAN; NOTE; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 34548858431     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070582     Document Type: Note

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66
2. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176
3. Buijs JT, Rentsch CA, van der Horst G, van Overveld PGM, Schwaninger R, Henriquez NV, Papapoulos SE, Pelger RCM, Vukicevic S, Cecchini MG, Löwik CWGM, van der Pluijm G: BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007, 171:1047-1057
4. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458
5. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005, 102:13909-13914
6. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549
7. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206
8. Massagué J, Gomis RR: The logic of TGFβ signaling. FEBS Lett 2006, 580:2811-2820
9. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ: Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006, 66:6714-6721
10. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, Andre J, Delmas V, Larue L, Guise TA, Mauviel A: Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007, 67:2317-2324
11. Stebbins EG, Mohammad KS, Niewolna M, McKenna CR, Mison AP, Schimmoller F, Murphy A, Chakravarty S, Dugar S, Higgins LS, Wong DH, Guise TA: SD-208, a small molecule inhibitor of transforming growth factor-β receptor I kinase reduces breast cancer metastases to bone and improves survival in a mouse model. J Bone Miner Res 2005, 20:S55
12. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, ten Dijke P: The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006, 66:2202-2209
13. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968
14. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109:1551-1559
15. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL: Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor betal. Mol Cell Biol 2003, 23:8691-8703
16. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003, 100:8430-8435
17. Masuda H, Fukabori Y, Nakano K, Shimizu N, Yamanaka H: Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 2004, 59:101-106
18. Thomas R, Anderson WA, Raman V, Reddi AH: Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate 1998, 37:236-245
19. Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935
20. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468
21. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100:10954-10959
22. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P: Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005, 65:5769-5777
23. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, Borset M: Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004, 23:3024-3032
24. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET: Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005, 65:8274-8285
25. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR: Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005, 20:2189-2199
26. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38:154-166
27. Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki TC, Yamanaka H: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003, 54:268-274
28. Jena N, Martin-Seisdedos C, McCue P, Croce CM: BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. Exp Cell Res 1997, 230:28-37